<!DOCTYPE html><html lang="en-us" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  
  
  
  <meta name="generator" content="Wowchemy 4.8.0 for Hugo">
  

  

  
  

  
  
  
  
  
    
    
    
  
  

  

  
  
  
    
  
  <meta name="description" content="Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in some but not all breast cancer cell lines. Breast cancers can be divided into those which express the estrogen (ER) and progesterone (PR) receptors, those with HER-2 amplification, and those without expression of ER, PR, or HER-2 amplification (referred to as basal or triple-negative breast cancer). We tested a panel of 20 breast cancer cell lines representing the different types of breast cancer to evaluate if the molecular phenotype of the breast cancer cells determined their response to TRAIL. The most striking finding was that eight of eleven triple-negative cell lines are sensitive to TRAIL-mediated apoptosis. The eight TRAIL-sensitive triple-negative cell lines have a mesenchymal phenotype while the three TRAIL-resistant triple-negative cell lines have an epithelial phenotype. Two of five cell lines with HER-2 amplification were sensitive to TRAIL and none of the five ER positive cell lines were sensitive. RNAi-mediated knockdown of TRAIL receptor expression demonstrated that TRAIL Receptor 2 (TRAIL-R2) mediates the effects of TRAIL, even when both TRAIL-R1 and TRAIL-R2 are expressed. Finally, inhibition of EGFR, expressed in both TRAIL-sensitive and TRAIL-resistant triple-negative breast cancer cell lines, using a small molecule tyrosine kinase inhibitor (AG1478), enhanced TRAIL-induced apoptosis in TRAIL-sensitive cell lines but did not convert resistant cells into TRAIL-sensitive cells. Together, these findings suggest that a subset of triple-negative breast cancer, those with mesenchymal features, may be the most likely to benefit from TRAIL targeted therapy. These findings could form the basis to select breast cancer patients for clinical trials of TRAIL-R2 ligands.">

  
  <link rel="alternate" hreflang="en-us" href="https://seandavi.github.io/publication/pmid-18266105/">

  







  




  
  
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  

  
  
  
  <meta name="theme-color" content="#3f51b5">
  

  
  
  
  <script src="/js/mathjax-config.js"></script>
  

  
  
  
  
    
    
      <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.9.0/css/academicons.min.css" integrity="sha512-W4yqoT1+8NLkinBLBZko+dFB2ZbHsYLDdr50VElllRcNt2Q4/GSs6u71UHKxB7S6JEMCp5Ve4xjh3eGQl/HRvg==" crossorigin="anonymous">
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.14.0/css/all.min.css" integrity="sha256-FMvZuGapsJLjouA6k7Eo2lusoAX9i0ShlWFG6qt7SLc=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/styles/atom-one-light.min.css" crossorigin="anonymous" title="hl-light">
        <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/styles/atom-one-light.min.css" crossorigin="anonymous" title="hl-dark" disabled>
      
    

    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.7.1/leaflet.min.css" integrity="sha512-1xoFisiGdy9nvho8EgXuXvnpR5GAMSjFwp40gSRE3NwdUdIMIKuPa7bqoUhLD0O/5tPNhteAsE5XyyMi5reQVA==" crossorigin="anonymous">
    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.2.2/lazysizes.min.js" integrity="sha512-TmDwFLhg3UA4ZG0Eb4MIyT1O1Mb+Oww5kFG0uHqXsdbyZz9DcvYQhKpGgNkamAI6h2lGGZq2X8ftOJvF/XjTUg==" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-chtml.js" integrity="" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    

  

  
  
  
    
      
      
      <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
    
  

  
  
  
  
  <link rel="stylesheet" href="/css/wowchemy.css">

  





<script async src="https://www.googletagmanager.com/gtag/js?id=UA-93043521-1"></script>
<script>
  window.dataLayer = window.dataLayer || [];

  function gtag() {
      dataLayer.push(arguments);
  }

  function trackOutboundLink(url, target) {
    gtag('event', 'click', {
         'event_category': 'outbound',
         'event_label': url,
         'transport_type': 'beacon',
         'event_callback': function () {
           if (target !== '_blank') {
             document.location = url;
           }
         }
    });
    console.debug("Outbound link clicked: " + url);
  }

  function onClickCallback(event) {
    if ((event.target.tagName !== 'A') || (event.target.host === window.location.host)) {
      return;
    }
    trackOutboundLink(event.target, event.target.getAttribute('target'));  
  }

  gtag('js', new Date());
  gtag('config', 'UA-93043521-1', {});

  
  document.addEventListener('click', onClickCallback, false);
</script>


  


  
  

  

  <link rel="manifest" href="/index.webmanifest">
  <link rel="icon" type="image/png" href="/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_32x32_fill_lanczos_center_3.png">
  <link rel="apple-touch-icon" type="image/png" href="/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_192x192_fill_lanczos_center_3.png">

  <link rel="canonical" href="https://seandavi.github.io/publication/pmid-18266105/">

  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="twitter:site" content="@seandavis12">
  <meta property="twitter:creator" content="@seandavis12">
  
  <meta property="og:site_name" content="seandavi(s12)">
  <meta property="og:url" content="https://seandavi.github.io/publication/pmid-18266105/">
  <meta property="og:title" content="TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype | seandavi(s12)">
  <meta property="og:description" content="Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in some but not all breast cancer cell lines. Breast cancers can be divided into those which express the estrogen (ER) and progesterone (PR) receptors, those with HER-2 amplification, and those without expression of ER, PR, or HER-2 amplification (referred to as basal or triple-negative breast cancer). We tested a panel of 20 breast cancer cell lines representing the different types of breast cancer to evaluate if the molecular phenotype of the breast cancer cells determined their response to TRAIL. The most striking finding was that eight of eleven triple-negative cell lines are sensitive to TRAIL-mediated apoptosis. The eight TRAIL-sensitive triple-negative cell lines have a mesenchymal phenotype while the three TRAIL-resistant triple-negative cell lines have an epithelial phenotype. Two of five cell lines with HER-2 amplification were sensitive to TRAIL and none of the five ER positive cell lines were sensitive. RNAi-mediated knockdown of TRAIL receptor expression demonstrated that TRAIL Receptor 2 (TRAIL-R2) mediates the effects of TRAIL, even when both TRAIL-R1 and TRAIL-R2 are expressed. Finally, inhibition of EGFR, expressed in both TRAIL-sensitive and TRAIL-resistant triple-negative breast cancer cell lines, using a small molecule tyrosine kinase inhibitor (AG1478), enhanced TRAIL-induced apoptosis in TRAIL-sensitive cell lines but did not convert resistant cells into TRAIL-sensitive cells. Together, these findings suggest that a subset of triple-negative breast cancer, those with mesenchymal features, may be the most likely to benefit from TRAIL targeted therapy. These findings could form the basis to select breast cancer patients for clinical trials of TRAIL-R2 ligands."><meta property="og:image" content="https://seandavi.github.io/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_3.png">
  <meta property="twitter:image" content="https://seandavi.github.io/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_3.png"><meta property="og:locale" content="en-us">
  
    
      <meta property="article:published_time" content="2021-08-21T20:26:28&#43;00:00">
    
    <meta property="article:modified_time" content="2021-05-08T15:13:09-06:00">
  

  


    









<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://seandavi.github.io/publication/pmid-18266105/"
  },
  "headline": "TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype",
  
  "datePublished": "2021-08-21T20:26:28Z",
  "dateModified": "2021-05-08T15:13:09-06:00",
  
  "author": {
    "@type": "Person",
    "name": "M. Rahman"
  },
  
  "publisher": {
    "@type": "Organization",
    "name": "seandavi(s12)",
    "logo": {
      "@type": "ImageObject",
      "url": "https://seandavi.github.io/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_192x192_fill_lanczos_center_3.png"
    }
  },
  "description": "Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in some but not all breast cancer cell lines. Breast cancers can be divided into those which express the estrogen (ER) and progesterone (PR) receptors, those with HER-2 amplification, and those without expression of ER, PR, or HER-2 amplification (referred to as basal or triple-negative breast cancer). We tested a panel of 20 breast cancer cell lines representing the different types of breast cancer to evaluate if the molecular phenotype of the breast cancer cells determined their response to TRAIL. The most striking finding was that eight of eleven triple-negative cell lines are sensitive to TRAIL-mediated apoptosis. The eight TRAIL-sensitive triple-negative cell lines have a mesenchymal phenotype while the three TRAIL-resistant triple-negative cell lines have an epithelial phenotype. Two of five cell lines with HER-2 amplification were sensitive to TRAIL and none of the five ER positive cell lines were sensitive. RNAi-mediated knockdown of TRAIL receptor expression demonstrated that TRAIL Receptor 2 (TRAIL-R2) mediates the effects of TRAIL, even when both TRAIL-R1 and TRAIL-R2 are expressed. Finally, inhibition of EGFR, expressed in both TRAIL-sensitive and TRAIL-resistant triple-negative breast cancer cell lines, using a small molecule tyrosine kinase inhibitor (AG1478), enhanced TRAIL-induced apoptosis in TRAIL-sensitive cell lines but did not convert resistant cells into TRAIL-sensitive cells. Together, these findings suggest that a subset of triple-negative breast cancer, those with mesenchymal features, may be the most likely to benefit from TRAIL targeted therapy. These findings could form the basis to select breast cancer patients for clinical trials of TRAIL-R2 ligands."
}
</script>

  

  


  


  





  <title>TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype | seandavi(s12)</title>

</head>


<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" class=" ">

  
  
  
  
    <script>const isSiteThemeDark = false;</script>
  
  
  <script src="/js/load-theme.js"></script>

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search" class="form-control">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  












<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/">seandavi(s12)</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/">seandavi(s12)</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#about"><span>About</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#posts"><span>Posts</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#talks"><span>Talks</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#publications"><span>Publications</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/project/"><span>Projects</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#contact"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#" aria-label="Search"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      
      

      

    </ul>

  </div>
</nav>



  <div class="pub">

  












  

  
  
  
<div class="article-container pt-3">
  <h1>TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype</h1>

  

  
    


<div class="article-metadata">

  
  
  
  
  <div>
    

  
  <span ><a href="/authors/m.-rahman/">M. Rahman</a></span>, <span ><a href="/authors/s.-r.-davis/">S. R. Davis</a></span>, <span ><a href="/authors/j.-g.-pumphrey/">J. G. Pumphrey</a></span>, <span ><a href="/authors/j.-bao/">J. Bao</a></span>, <span ><a href="/authors/m.-m.-nau/">M. M. Nau</a></span>, <span ><a href="/authors/p.-s.-meltzer/">P. S. Meltzer</a></span>, <span ><a href="/authors/s.-lipkowitz/">S. Lipkowitz</a></span>
  </div>
  
  

  
  <span class="article-date">
    
    
      
    
    January 2009
  </span>
  

  

  

  
  
  
  <span class="middot-divider"></span>
  <a href="/publication/pmid-18266105/#disqus_thread"></a>
  

  
  

</div>

    











  



<div class="btn-links mb-3">
  
  








  





<button type="button" class="btn btn-outline-primary my-1 mr-1 js-cite-modal"
        data-filename="/publication/pmid-18266105/cite.bib">
  Cite
</button>















</div>


  
</div>



  <div class="article-container">

    
    <h3>Abstract</h3>
    <p class="pub-abstract">Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis in some but not all breast cancer cell lines. Breast cancers can be divided into those which express the estrogen (ER) and progesterone (PR) receptors, those with HER-2 amplification, and those without expression of ER, PR, or HER-2 amplification (referred to as basal or triple-negative breast cancer). We tested a panel of 20 breast cancer cell lines representing the different types of breast cancer to evaluate if the molecular phenotype of the breast cancer cells determined their response to TRAIL. The most striking finding was that eight of eleven triple-negative cell lines are sensitive to TRAIL-mediated apoptosis. The eight TRAIL-sensitive triple-negative cell lines have a mesenchymal phenotype while the three TRAIL-resistant triple-negative cell lines have an epithelial phenotype. Two of five cell lines with HER-2 amplification were sensitive to TRAIL and none of the five ER positive cell lines were sensitive. RNAi-mediated knockdown of TRAIL receptor expression demonstrated that TRAIL Receptor 2 (TRAIL-R2) mediates the effects of TRAIL, even when both TRAIL-R1 and TRAIL-R2 are expressed. Finally, inhibition of EGFR, expressed in both TRAIL-sensitive and TRAIL-resistant triple-negative breast cancer cell lines, using a small molecule tyrosine kinase inhibitor (AG1478), enhanced TRAIL-induced apoptosis in TRAIL-sensitive cell lines but did not convert resistant cells into TRAIL-sensitive cells. Together, these findings suggest that a subset of triple-negative breast cancer, those with mesenchymal features, may be the most likely to benefit from TRAIL targeted therapy. These findings could form the basis to select breast cancer patients for clinical trials of TRAIL-R2 ligands.</p>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            
            
            <a href="/publication/#2">
              Journal article
            </a>
            
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Publication</div>
          <div class="col-12 col-md-9"><em>Breast Cancer Res. Treat.</em></div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    <div class="space-below"></div>

    <div class="article-style"></div>

    








<div class="share-box" aria-hidden="true">
  <ul class="share">
    
      
      
      
        
      
      
      
      <li>
        <a href="https://twitter.com/intent/tweet?url=https://seandavi.github.io/publication/pmid-18266105/&amp;text=TRAIL%20induces%20apoptosis%20in%20triple-negative%20breast%20cancer%20cells%20with%20a%20mesenchymal%20phenotype" target="_blank" rel="noopener" class="share-btn-twitter">
          <i class="fab fa-twitter"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.facebook.com/sharer.php?u=https://seandavi.github.io/publication/pmid-18266105/&amp;t=TRAIL%20induces%20apoptosis%20in%20triple-negative%20breast%20cancer%20cells%20with%20a%20mesenchymal%20phenotype" target="_blank" rel="noopener" class="share-btn-facebook">
          <i class="fab fa-facebook"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="mailto:?subject=TRAIL%20induces%20apoptosis%20in%20triple-negative%20breast%20cancer%20cells%20with%20a%20mesenchymal%20phenotype&amp;body=https://seandavi.github.io/publication/pmid-18266105/" target="_blank" rel="noopener" class="share-btn-email">
          <i class="fas fa-envelope"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.linkedin.com/shareArticle?url=https://seandavi.github.io/publication/pmid-18266105/&amp;title=TRAIL%20induces%20apoptosis%20in%20triple-negative%20breast%20cancer%20cells%20with%20a%20mesenchymal%20phenotype" target="_blank" rel="noopener" class="share-btn-linkedin">
          <i class="fab fa-linkedin-in"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="whatsapp://send?text=TRAIL%20induces%20apoptosis%20in%20triple-negative%20breast%20cancer%20cells%20with%20a%20mesenchymal%20phenotype%20https://seandavi.github.io/publication/pmid-18266105/" target="_blank" rel="noopener" class="share-btn-whatsapp">
          <i class="fab fa-whatsapp"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://service.weibo.com/share/share.php?url=https://seandavi.github.io/publication/pmid-18266105/&amp;title=TRAIL%20induces%20apoptosis%20in%20triple-negative%20breast%20cancer%20cells%20with%20a%20mesenchymal%20phenotype" target="_blank" rel="noopener" class="share-btn-weibo">
          <i class="fab fa-weibo"></i>
        </a>
      </li>
    
  </ul>
</div>











  
  
    




  
    




  
    




  
    




  
    




  
    




  
    




  





<section id="comments">
  
    
<div id="disqus_thread"></div>
<script>
  var disqus_config = function () {
    
    
    
  };
  (function() {
    if (["localhost", "127.0.0.1"].indexOf(window.location.hostname) != -1) {
      document.getElementById('disqus_thread').innerHTML = 'Disqus comments not available by default when the website is previewed locally.';
      return;
    }
    var d = document, s = d.createElement('script'); s.async = true;
    s.src = 'https://' + "seandavi-github-io" + '.disqus.com/embed.js';
    s.setAttribute('data-timestamp', +new Date());
    (d.head || d.body).appendChild(s);
  })();
</script>
<noscript>Please enable JavaScript to view the <a href="https://disqus.com/?ref_noscript">comments powered by Disqus.</a></noscript>
<a href="https://disqus.com" class="dsq-brlink">comments powered by <span class="logo-disqus">Disqus</span></a>


  
</section>










  </div>
</div>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.5.1/jquery.min.js" integrity="sha256-9/aliU8dGd2tb6OSsuzixeV4y/faTqgFtohetphbbj0=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/instant.page/5.1.0/instantpage.min.js" integrity="sha512-1+qUtKoh9XZW7j+6LhRMAyOrgSQKenQ4mluTR+cvxXjP1Z54RxZuzstR/H9kgPXQsVB8IW7DMDFUJpzLjvhGSQ==" crossorigin="anonymous"></script>

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/mermaid/8.8.0/mermaid.min.js" integrity="sha512-ja+hSBi4JDtjSqc4LTBsSwuBT3tdZ3oKYKd07lTVYmCnTCor56AnRql00ssqnTOR9Ss4gOP/ROGB3SfcJnZkeg==" crossorigin="anonymous" title="mermaid"></script>
      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/highlight.min.js" integrity="sha512-TDKKr+IvoqZnPzc3l35hdjpHD0m+b2EC2SrLEgKDRWpxf2rFCxemkgvJ5kfU48ip+Y+m2XVKyOCD85ybtlZDmw==" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/languages/r.min.js"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/languages/python.min.js"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/languages/javascript.min.js"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/languages/html.min.js"></script>
        
      

    

    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/leaflet/1.7.1/leaflet.min.js" integrity="sha512-SeiQaaDh73yrb56sTW/RgVdi/mMqNeM2oBwubFHagc5BkixSpP1fvqF47mKzPGWYSSy4RwbBunrJBQ4Co8fRWA==" crossorigin="anonymous"></script>
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks",
        'slides' : "Slides"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    

    
    

    
    
    <script id="dsq-count-scr" src="https://seandavi-github-io.disqus.com/count.js" async></script>
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/js/wowchemy.min.434af0ebce9e15b273b954d65feb39c7.js"></script>

    






  
  
  <div class="container">
    <footer class="site-footer">
  

  <p class="powered-by">
    © 2016-2020
  </p>

  
  






  <p class="powered-by">
    
    Published with
    <a href="https://wowchemy.com" target="_blank" rel="noopener">Wowchemy</a>  —
    the free, <a href="https://github.com/wowchemy/wowchemy-hugo-modules" target="_blank" rel="noopener">
    open source</a> website builder that empowers creators.
    

    
    <span class="float-right" aria-hidden="true">
      <a href="#" class="back-to-top">
        <span class="button_icon">
          <i class="fas fa-chevron-up fa-2x"></i>
        </span>
      </a>
    </span>
    
  </p>
</footer>

  </div>
  

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

</body>
</html>
